KSKsenia S. Sokolova

Ksenia S. Sokolova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ksenia S. Sokolova has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Effectiveness and safety of fenofibrate therapy in primary biliary cholangitis in real-life clinical practice

    by M. K. Prashnova, K. L. Raikhelson, V. P. Gomonova, E. V. Pazenko, M. V. Marchenko, K. S. Sokolova

    Introduction. Randomized clinical trials and meta-analyses demonstrate the efficacy of fibrate therapy in ursodeoxycholic acid (UDCA)-resistant patients with primary biliary cirrhosis (PBC). However, there is still limited information on the efficacy and safety of fenofibrate use in routine clinical practice in PBC. Aim. To evaluate the efficacy and safety of fenofibrate therapy in outpatients with PBC, who have an insufficient response and/ or are intolerant to UDCA. Materials and methods . A retrospective assessment of treatment response (complete biochemical response, Paris-II, GLOBE scores), adverse events, and disease progression was performed in 63 patients with PBC refractory to UDCA monotherapy, receiving fenofibrate at 145–200 mg daily in combination with UDCA at 13–15 mg/kg/day for at least 6 months (average 21.0 ± 12.8 months). The mean disease duration before diagnosis was 35.4 ± 38.4 months, and the proportion of patients with advanced-stage PBC before therapy was 68.3%. Results . Paris-II, GLOBE and complete biochemical response rates were 54.0%, 58.7% and 25.4%, respectively, and were negatively associated with the presence of clinically significant portal hypertension (CSPH) (p = 0.0006, p = 0.006, p = 0.001, respectively). The addition of fenofibrate to UDCA reduced the incidence of skin itching from 60.6% to 18.2% (p = 0.0005). The following adverse events (AE) were reported during fenofibrate therapy: myalgia (n = 10); asymptomatic cholecystolithiasis (n = 6); an increase in ALT by 5 or more times from baseline levels, which regressed upon drug discontinuation (n = 2); one patient had a serious AE – bleeding from esophageal varices, probably not related to the medication. A 1.7-fold increase in the incidence of anemia associated with comorbid conditions was noted. Fenofibrate therapy was not associated with a statistically significant increase in the incidence of advanced-stage PBC, clinically significant portal hypertension, or the MELD score in patients with cirrhosis. Conclusions . The addition of fenofibrate to UDCA in UDCA-refractory PBC increases the response rate and appears to be quite safe.

  • The role of the Kimura–Takemoto standard classification in determining follow-up groups for the prevention of stomach cancer in residents of the Northwestern Federal District of Russia

    by Alexander V. Tryapitsyn, Ksenia S. Sokolova, Andrey Yu. Baranovsky, Тряпицын Александр Валериевич, Барановский Андрей Юрьевич

    BACKGROUND: Precancerous changes in the gastric mucosa identified during morphological examination often have macroscopic equivalents on endoscopy. In a number of studies comparing endoscopic and morphological changes in atrophic gastritis, the authors emphasized the limitations of applying these data depending on the region. It is relevant to conduct a similar study regarding the population of the Northwestern Federal District of Russia. AIM: To assess the prevalence of histological stages of gastric mucosal atrophy in different types and stages according to the Kimura–Takemoto endoscopic classification in the population of the Northwestern Federal District of Russia. METHODS: In a single-center cohort study, medical records of patients who underwent outpatient videoesophagogastroduodenoscopy between 2020 and 2022 were analyzed, and cases of gastric mucosal atrophy of any type according to the Kimura–Takemoto classification (173 men and 189 women) were selected. Gastric biopsies were obtained from five standard sites in accordance with the modified Sydney System, followed by morphological verification of the atrophy stage according to the Operative Link on Gastritis Assessment (OLGA) system, and the type and extent of intestinal metaplasia were determined when detected. RESULTS: From 1,188 medical records, 362 cases of gastric mucosal atrophy were selected. Kimura–Takemoto type C1 atrophy was detected in 123 patients; however, upon histological examination of biopsies, only 3 (2.4%) of them were found to have severe atrophy, which is an indication for dispensary endoscopic follow-up according to the recommendations of the Russian Gastroenterological Association and the Russian Endoscopic Society. Type C2 was detected in 98 patients, of whom 12 (12.2%) were found to have indications for follow-up based on the results of morphological analysis. Type C3 changes were detected in 47 patients, 14 (29.8%) of whom required follow-up. Signs of severe atrophy of types O1, O2, and O3 were detected in 28, 18, and 48 patients, respectively. Of these, 14 (50.0%), 13 (72.2%), and 31 (64.6%), respectively, required follow-up according to morphological analysis data. CONCLUSIONS: Open-type endoscopic atrophy (O1–O3) according to the Kimura–Takemoto classification demonstrated high concordance with histological signs of severe atrophy and intestinal metaplasia, and in the majority of cases, patients required further endoscopic follow-up. In contrast, in endoscopically mild C1-type atrophy, there were no signs of severe atrophy. In cases of limited resources and the absence of visual signs of atypia, biopsy may not be performed in this category of patients in routine practice.

  • Immunologic and biochemical state of layers with conditionally high and low production longevit

    by Elena Yyldyrym, Georgy Laptev, Vitaly Morozov, Larisa Ilyina, Valentina Filippova, Elena Gorfunkel, Ksenia Sokolova, Daria Tyurina

    Comparative analysis of immunologic and biochemical state of layers with high and low supposed production longevity has been given in the paper. The most pronounced differences have been found in total blood protein content that has been lower ($p \leqslant 0.05$) supposed productive longevity group than in group with supposed high productive longevity that is $69.7 \pm 0.69$ g/l against $52.0 \pm 1.16$ g/l.